NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE American · Biotechnology · USD

Pelthos Therapeutics Inc. (PTHS) Stock Analysis

Pelthos Therapeutics Inc. (PTHS) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.

PTHS

$24.35

−$0.01 (−0.04%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PTHS with… →

PTHS Key Statistics

As of Sep 4, 2026
Trading
Open
$24.44
Previous Close
$24.36
Day's Range
24.01–24.79
52-Week Range
18.19–37.50
Volume
18.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
3.05
Valuation
Market Cap
$93.22M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.15
EPS (ttm)Profit attributable to each share over the last twelve months.
−28.63
Financials (FY)
Revenue (FY)
$16.80M
Net Income (FY)
−$43.32M
Profit marginThe share of revenue left as profit after all costs and taxes.
−199.50%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
3.83M
1-Year Return
−25.05%
Dividend and dates
Earnings Date
November 12, 2026
Avg Volume
57.82K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PTHS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−21.45%
2025+383.62%
2024 (partial year)−86.65%

As of September 4, 2026.

PTHS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$16.80M−$43.32M−257.9%
2024$0.00−$7.96M—
2023$0.00−$7.38M—
2022$0.00−$2.46M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$16.80M$7.43M−$32.43M−$43.32M−257.9%
2024$0.00$0.00−$7.57M−$7.96M—
2023$0.00—−$6.86M−$7.38M—
2022$0.00—−$2.32M−$2.46M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PTHS Valuation vs Biotechnology Median

Median of 656 stocks
MetricPTHSBiotechnology medianvs median
P/S ratio2.1515.260.1x the median
Profit margin−199.50%0.00%199.5 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Pelthos Therapeutics Inc. (PTHS) carries a market capitalisation of $93.22M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 92.

Over the past 52 weeks the price has ranged from $18.19 to $37.50. The most recent close on file for PTHS is $24.35, dated September 4, 2026. That is −$0.01 (−0.04%) against the previous close. The latest close sits 33.86% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $16.80M. The same year closed with a net loss of $43.32M. Profit margin runs at −199.5%. That is 199.5 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −28.63.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $16.80M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 2.15. On price-to-sales that is 0.1 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 3.05. Daily returns over the trailing 2 years annualize to a volatility of 149.18%. Over the trailing twelve months the price has returned −25.05%. The stored price history starts on February 16, 2024, and the total return since then is −49.27%.

Growth & Income

No dividend is on file for PTHS.

The record holds one complete calendar year, 2025, which returned +383.62%. So far in 2026 the price is −21.45%.

Peer Comparison

Pelthos Therapeutics Inc. (PTHS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Pelthos Therapeutics Inc. PTHS $93.22M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Pelthos Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Pelthos Therapeutics Inc.

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.

Visit website →